193 related articles for article (PubMed ID: 15624894)
21. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
[TBL] [Abstract][Full Text] [Related]
22. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
[TBL] [Abstract][Full Text] [Related]
23. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
Przepiorka D; Buadi FK; McClune B
Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
[TBL] [Abstract][Full Text] [Related]
24. VFEND® (voriconazole)-associated hypoglycaemia without identified drug interaction.
Lyoen M; Rostain F; Grimault A; Minello A; Sgro C
Fundam Clin Pharmacol; 2013 Oct; 27(5):570-1. PubMed ID: 22834415
[TBL] [Abstract][Full Text] [Related]
25. Lack of cross-hepatotoxicity between voriconazole and posaconazole.
Foo H; Gottlieb T
Clin Infect Dis; 2007 Sep; 45(6):803-5. PubMed ID: 17712772
[No Abstract] [Full Text] [Related]
26. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
[TBL] [Abstract][Full Text] [Related]
27. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole.
Denning DW; Griffiths CE
Clin Exp Dermatol; 2001 Nov; 26(8):648-53. PubMed ID: 11722447
[TBL] [Abstract][Full Text] [Related]
28. Voriconazole is effective as secondary antifungal prophylaxis in leukemia patients with prior pulmonary fungal disease: case series and review of literature.
Masamoto Y; Nannya Y; Kurokawa M
J Chemother; 2011 Feb; 23(1):17-23. PubMed ID: 21482489
[TBL] [Abstract][Full Text] [Related]
29. Pharmacoeconomics of voriconazole in the management of invasive fungal infections.
Al-Badriyeh D; Heng SC; Neoh CF; Slavin M; Stewart K; Kong DC
Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):623-36. PubMed ID: 21155694
[TBL] [Abstract][Full Text] [Related]
30. Voriconazole: a new triazole antifungal.
Sabo JA; Abdel-Rahman SM
Ann Pharmacother; 2000 Sep; 34(9):1032-43. PubMed ID: 10981251
[TBL] [Abstract][Full Text] [Related]
31. Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia.
Fournier S; Pavageau W; Feuillhade M; Deplus S; Zagdanski AM; Verola O; Dombret H; Molina JM
Eur J Clin Microbiol Infect Dis; 2002 Dec; 21(12):892-6. PubMed ID: 12525928
[TBL] [Abstract][Full Text] [Related]
32. Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population.
Imataki O; Ohnishi H; Kitanaka A; Kubota Y; Ishida T; Tanaka T
Int J Hematol; 2008 Jul; 88(1):3-6. PubMed ID: 18574651
[TBL] [Abstract][Full Text] [Related]
33. Azole-based chemoprophylaxis of invasive fungal infections in paediatric patients with acute leukaemia: an internal audit.
Yunus S; Pieper S; Kolve H; Goletz G; Jürgens H; Groll AH
J Antimicrob Chemother; 2014 Mar; 69(3):815-20. PubMed ID: 24198097
[TBL] [Abstract][Full Text] [Related]
34. The safety of voriconazole.
Potoski BA; Brown J
Clin Infect Dis; 2002 Nov; 35(10):1273-5. PubMed ID: 12410490
[No Abstract] [Full Text] [Related]
35. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
[TBL] [Abstract][Full Text] [Related]
36. Idiosyncratic nature of voriconazole photosensitivity in children undergoing cancer therapy.
Hansford JR; Cole C; Blyth CC; Gottardo NG
J Antimicrob Chemother; 2012 Jul; 67(7):1807-9. PubMed ID: 22454488
[No Abstract] [Full Text] [Related]
37. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases.
Mouas H; Lutsar I; Dupont B; Fain O; Herbrecht R; Lescure FX; Lortholary O;
Clin Infect Dis; 2005 Apr; 40(8):1141-7. PubMed ID: 15791514
[TBL] [Abstract][Full Text] [Related]
38. Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan.
Koh H; Hino M; Ohta K; Iino M; Urase F; Yamaguchi M; Yamanouchi J; Usui N; Yoshida M; Tanimoto M; Ohyashiki K; Urabe A; Tamura K; Kanamaru A; Masaoka T
J Infect Chemother; 2013 Dec; 19(6):1126-34. PubMed ID: 23813092
[TBL] [Abstract][Full Text] [Related]
39. Voriconazole in newborns.
Kohli V; Taneja V; Sachdev P; Joshi R
Indian Pediatr; 2008 Mar; 45(3):236-8. PubMed ID: 18367773
[TBL] [Abstract][Full Text] [Related]
40. Severe acute hypokalaemia secondary to voriconazole. Uncommon pharmacological causes of hypokalaemia.
González Rozas M; Alvarez Tundidor S; Pineda Alonso M
Nefrologia; 2011; 31(1):112-3. PubMed ID: 21270925
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
